Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | HB-202 |
Trade Name | |
Synonyms | HB202|HB 202 |
Drug Descriptions |
HB-202 is a replication-defective arenavirus-based cancer vaccine that expresses an HPV16-derived E6/E7 fusion protein, which potentially induces host immune response, thereby resulting in the lysis of HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C173149 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + HB-201 + HB-202 + Paclitaxel | Carboplatin HB-201 HB-202 Paclitaxel | 0 | 1 |
HB-201 + HB-202 | HB-201 HB-202 | 0 | 2 |
HB-201 + HB-202 + Nivolumab | HB-201 HB-202 Nivolumab | 0 | 1 |
HB-202 | HB-202 | 0 | 0 |